Loading company…
Shenzhen TargetRx develops and sells small-molecule targeted anti-cancer drugs, including candidates in Phase I trials.
Established in 2014 and based in Shenzhen, China, TargetRx develops and sells small-molecule targeted anti-cancer drugs and provides R&D services. Its pipeline includes TGRX-678 for chronic myelogenous leukemia and TGRX-326 for non-small cell lung cancer, both in Phase I trials. Yihan Wang is founder, chairman and CEO. In January 2025 it raised USD 50 million in Series C funding for overseas clinical studies of several innovative drugs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in